Expanding the use of hepatitis C-viremic kidney donors.
Journal Article (Journal Article)
Direct-acting antivirals have revolutionized the treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease, with implications for the timing of antiviral treatment among kidney transplant candidates and for the use of HCV viremic donors. A recent consensus conference reviewed the available data on the safety and cost-effectiveness of expanding access to HCV-positive organs to HCV-negative recipients. Early trials are promising, but larger trials and a plan for obtaining HCV therapy in the posttransplantation period are needed. Implications for the larger transplant community also need to be considered.
Full Text
Duke Authors
Cited Authors
- Sawinski, D; Wyatt, CM; Locke, JE
Published Date
- November 2017
Published In
Volume / Issue
- 92 / 5
Start / End Page
- 1031 - 1033
PubMed ID
- 29055420
Electronic International Standard Serial Number (EISSN)
- 1523-1755
Digital Object Identifier (DOI)
- 10.1016/j.kint.2017.09.002
Language
- eng
Conference Location
- United States